FOSTEMSAVIR DISODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H24N7O8P.2Na
Molecular Weight	627.4535
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].COC1=CN=C(N2C=NC(C)=N2)C3=C1C(=CN3COP([O-])([O-])=O)C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5

InChI

InChIKey=QJNUSJLDVYPCNN-UHFFFAOYSA-L

InChI=1S/C25H26N7O8P.2Na/c1-16-27-14-32(28-16)23-21-20(19(39-2)12-26-23)18(13-31(21)15-40-41(36,37)38)22(33)25(35)30-10-8-29(9-11-30)24(34)17-6-4-3-5-7-17;;/h3-7,12-14H,8-11,15H2,1-2H3,(H2,36,37,38);;/q;2*+1/p-2

HIDE SMILES / InChI

Molecular Formula	C25H24N7O8P
Molecular Weight	581.4739
Charge	-2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://aidsinfo.nih.gov/drugs/508/fostemsavir/0/patient | https://www.hiv.uw.edu/page/treatment/drugs/fostemsavir | https://www.ncbi.nlm.nih.gov/pubmed/27922453https://www.ncbi.nlm.nih.gov/pubmed/25401969
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22547625 https://www.ncbi.nlm.nih.gov/pubmed/23774428

Temsavir (BMS-626529) is an attachment inhibitor (AI) in clinical development (administered as prodrug BMS-663068) that binds to HIV-1 gp120. Temsavir displays in vitro activity against HIV-1 envelopes with C-C chemokine receptor type 5 (CCR5-), C-X-C chemokine receptor type 4 (CXCR4), and dual tropism. It also is active against almost all HIV-1 subtypes tested except for subtype CRF01-AE and possibly group O. Temsavir can inhibit both CD4-induced and CD4-independent formation of the "open state" four-stranded gp120 bridging sheet, and the subsequent formation and exposure of the chemokine co-receptor binding site. This unique mechanism of action prevents the initial interaction of HIV-1 with the host CD4+ T cell, and subsequent HIV-1 binding and entry. Temsavir is administered as a phosphonooxymethyl ester prodrug (BMS-663068), which was developed to improve the solubility and dissolution of Temsavir. Temsavir is currently being investigated clinically through the use of the prodrug BMS-663068, and a Phase III study of BMS-663068 in HIV-1-infected treatment-experienced subjects is ongoing (NCT02362503).

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human immunodeficiency virus 1 33 Target ID: CHEMBL378 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22547625	Inhibitor 8297
Human immunodeficiency virus 1 33 Target ID: CHEMBL378 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22547625	Inhibitor 8297		2.26 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 151 Sources: http://adisinsight.springer.com/drugs/800031504 https://clinicaltrials.gov/ct2/show/NCT02362503	Primary		Phase III 656	Unknown Approved Use Unknown
HIV-1 infection 151 Sources: https://clinicaltrials.gov/ct2/show/NCT02362503	Primary		Phase III 656	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
1770 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: other antiretroviral drugs	other antiretroviral drugs	TEMSAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.39 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22896665/	1200 mg 2 times / day multiple, oral dose: 1200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TEMSAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FED
2.55 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01009814	1200 mg single, oral dose: 1200 mg route of administration: oral experiment type: single co-administered:		TEMSAVIR plasma	Homo sapiens
3.18 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01009814	1200 mg 1 times / 12 hours multiple, oral dose: 1200 mg route of administration: oral experiment type: multiple co-administered:		TEMSAVIR plasma	Homo sapiens
3.38999999999999 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01009814	1200 mg 1 times / 12 hours multiple, oral dose: 1200 mg route of administration: oral experiment type: multiple co-administered:		TEMSAVIR plasma	Homo sapiens
3.61 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01009814	1200 mg 1 times / 12 hours multiple, oral dose: 1200 mg route of administration: oral experiment type: multiple co-administered:		TEMSAVIR plasma	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
12900 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: other antiretroviral drugs	other antiretroviral drugs	TEMSAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
42.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22896665/	1200 mg 2 times / day multiple, oral dose: 1200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TEMSAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FED
13.8 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01009814	1200 mg single, oral dose: 1200 mg route of administration: oral experiment type: single co-administered:		TEMSAVIR plasma	Homo sapiens
19.5 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01009814	1200 mg 1 times / 12 hours multiple, oral dose: 1200 mg route of administration: oral experiment type: multiple co-administered:		TEMSAVIR plasma	Homo sapiens
22.5 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01009814	1200 mg 1 times / 12 hours multiple, oral dose: 1200 mg route of administration: oral experiment type: multiple co-administered:		TEMSAVIR plasma	Homo sapiens
42.6 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01009814	1200 mg 1 times / 12 hours multiple, oral dose: 1200 mg route of administration: oral experiment type: multiple co-administered:		TEMSAVIR plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
11 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		TEMSAVIR plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
26.9% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		TEMSAVIR plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	Disc. AE: Immune reconstitution inflammatory syndrome... Other AEs: Nausea, Diarrhea... AEs leading to discontinuation/dose reduction: Immune reconstitution inflammatory syndrome (grade 3, 3%) Other AEs: Nausea (grade 1-4, 10%) Diarrhea (grade 1-4, 4%) Headache (grade 1-4, 4%) Abdominal pain (grade 1-4, 3%) Dyspepsia (grade 1-4, 3%) Fatigue (grade 1-4, 3%) Rash (grade 1-4, 3%) Sleep disturbance (grade 1-4, 3%) Immune reconstitution inflammatory syndrome (grade 1-4, 2%) Somnolence (grade 1-4, 2%) Vomiting (grade 1-4, 2%) ALT increased (grade 3-4, 5%) AST increased (grade 3-4, 4%) Direct bilirubin increased (grade 3, 7%) Bilirubin increased (grade 3-4, 3%) Creatinine increased (grade 3-4, 19%) Creatine kinase increased (grade 3-4, 2%) Hemoglobin decreased (grade 3-4, 6%) Hyperglycemia (grade 3-4, 4%) Lipase increased (grade 3-4, 5%) Neutrophils reduced (grade 3-4, 4%) Blood triglycerides increased (grade 3-4, 5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: ritonavir(100 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	healthy, 18-49 years n = 18 Health Status: healthy Age Group: 18-49 years Sex: M+F Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	Other AEs: Scleral icterus, Abdominal pain... Other AEs: Scleral icterus (5.6%) Abdominal pain (5.6%) Nausea (5.6%) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: atazanavir(300 mg; oral; 1/day) ritonavir(100 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	healthy, 18-49 years n = 36 Health Status: healthy Age Group: 18-49 years Sex: M+F Population Size: 36 Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	Other AEs: Scleral icterus, Abdominal pain... Other AEs: Scleral icterus (27.8%) Abdominal pain (11.1%) Headache (13.9%) Dizziness (5.6%) Nausea (8.3%) Musculoskeletal chest pain (2.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	healthy, 18-49 years n = 36 Health Status: healthy Age Group: 18-49 years Sex: M+F Population Size: 36 Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	Other AEs: Headache... Other AEs: Headache (5.6%) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/
1050 mg 2 times / day steady, oral (mean) Studied dose Dose: 1050 mg, 2 times / day Route: oral Route: steady Dose: 1050 mg, 2 times / day Co-administed with:: raltegravir and tenofovir disoproxil fumarate Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	unhealthy, adults n = 200 Health Status: unhealthy Condition: HIV-1 infection Age Group: adults Sex: M+F Population Size: 200 Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	Other AEs: Headache... Other AEs: Headache (grade 1, 14%) Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/
1200 mg 1 times / day steady, oral Studied dose Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Co-administed with:: raltegravir and tenofovir disoproxil fumarate Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	unhealthy, adults n = 50 Health Status: unhealthy Condition: HIV-1 infection Age Group: adults Sex: M+F Population Size: 50 Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	Disc. AE: Disseminated tuberculosis, Back pain... AEs leading to discontinuation/dose reduction: Disseminated tuberculosis (2%) Back pain (2%) Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/
400 mg 2 times / day steady, oral Studied dose Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Co-administed with:: raltegravir and tenofovir disoproxil fumarate Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	unhealthy, adults n = 50 Health Status: unhealthy Condition: HIV-1 infection Age Group: adults Sex: M+F Population Size: 50 Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	Disc. AE: Ischaemia... AEs leading to discontinuation/dose reduction: Ischaemia (2%) Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/
800 mg 2 times / day steady, oral Studied dose Dose: 800 mg, 2 times / day Route: oral Route: steady Dose: 800 mg, 2 times / day Co-administed with:: raltegravir and tenofovir disoproxil fumarate Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	unhealthy, adults n = 49 Health Status: unhealthy Condition: HIV-1 infection Age Group: adults Sex: M+F Population Size: 49 Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	Disc. AE: Bone tuberculosis, Acute renal failure... AEs leading to discontinuation/dose reduction: Bone tuberculosis (2%) Acute renal failure (2%) Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/
2400 mg 2 times / day steady, oral Highest studied dose Dose: 2400 mg, 2 times / day Route: oral Route: steady Dose: 2400 mg, 2 times / day Sources: https://www.fda.gov/media/140641/download	healthy n = 15 Health Status: healthy Population Size: 15 Sources: https://www.fda.gov/media/140641/download	Other AEs: QT interval prolonged... Other AEs: QT interval prolonged Sources: https://www.fda.gov/media/140641/download

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587 inducer 781	substrate 1037 inhibitor 1767	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B1 788 OATP1B3 706 CYP 111 UGT 35 BCRP 699 MATE2 263 CYP1A2 1524 CYP2B6 810 CYP2C8 911 CYP2C19 1478 CYP2A6 707 UGT1A1 204 UGT1A4 77 UGT1A9 116 UGT1A6 108 UGT2B7 146 P-gp 1461 OAT1 599 OAT3 642 MATE1 306 MRP2 383 NTCP 34 OCT2 647 BSEP 402 OCT1 512	CYP3A 191 P-gp 1537 BCRP 561 esterase 72 UGT 192 CYP1A1 349 CYP1A2 1054 CYP2A6 543 CYP1B1 92 CYP2B6 664 CYP2C8 693 CYP2C19 991 FMO3 67 CYP4A11 119 CYP2E1 667 CYP3A5 395	CYP1A2 701 CYP2B6 547

Drug as perpetrator

Target	Modality	Activity	Metabolite
OAT1 603	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 182.0	no [IC50 110 uM]	temsavir 5
OCT1 543	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 184.0	no [IC50 32.8 uM]	temsavir 5
UGT1A6 141	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 176.0	no [IC50 >10 uM]	temsavir 5
UGT1A9 121	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 176.0	no [IC50 >10 uM]	temsavir 5
UGT2B7 157	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 177.0	no [IC50 >10 uM]
UGT2B7 157	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 177.0	no [IC50 >10 uM]	temsavir 5
OCT2 648	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 184.0	no [IC50 >100 uM]	temsavir 5
UGT1A1 254	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 176.0	no [IC50 >100 uM]
UGT1A1 254	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 176.0	no [IC50 >100 uM]	temsavir 5
UGT1A4 80	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 176.0	no [IC50 >100 uM]
UGT1A4 80	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 176.0	no [IC50 >100 uM]	temsavir 5
UGT1A6 141	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 176.0	no [IC50 >100 uM]
UGT1A9 121	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 176.0	no [IC50 >100 uM]
BCRP 773	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 181.0	no [IC50 >250 uM]
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 181.0	no [IC50 >250 uM]
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 174.0	no [IC50 >40 uM]	temsavir 5
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 175.0	no [IC50 >40 uM]	temsavir 5
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 174.0	no [IC50 >40 uM]	temsavir 5
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 175.0	no [IC50 >40 uM]	temsavir 5
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 174.0	no [IC50 >40 uM]	temsavir 5
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 174.0	no [IC50 >40 uM]	temsavir 5
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 175.0	no [IC50 >40 uM]	temsavir 5
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 175.0	no [IC50 >40 uM]	temsavir 5
BSEP 403	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 184.0	no [IC50 >50 uM]	temsavir 5
MRP2 475	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 183.0	no [IC50 >50 uM]	temsavir 5
NTCP 35	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 183.0	no [IC50 >50 uM]	temsavir 5
OAT3 644	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 182.0	no [IC50 >50 uM]	temsavir 5
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 181.0	no [Inhibition 25 uM]	temsavir 5
CYP 147	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 36.0	no	temsavir 5
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 177.0	no	temsavir 5
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 178.0	no	temsavir 5
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 178.0	no	temsavir 5
UGT 59	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 36.0	no	temsavir 5
MATE2 263	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 36, 183	yes [IC50 12.2 uM]	temsavir 5
MATE1 308	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 182.0	yes [IC50 18.5 uM]	temsavir 5
BCRP 773	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 36, 114	yes	temsavir 5
OATP1B1 803	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 36, 114, 180	yes	temsavir 5
OATP1B3 715	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 36, 114, 181	yes	temsavir 5

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
UGT 192	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 35.0	minor	temsavir 5
CYP1A1 349	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173.0	no	temsavir 5
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173.0	no	temsavir 5
CYP1B1 92	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173.0	no	temsavir 5
CYP2A6 543	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173.0	no	temsavir 5
CYP2B6 664	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173.0	no	temsavir 5
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173.0	no	temsavir 5
CYP2C8 693	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173.0	no	temsavir 5
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173.0	no	temsavir 5
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173.0	no	temsavir 5
CYP2E1 667	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173.0	no	temsavir 5
CYP3A5 395	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173.0	no	temsavir 5
CYP4A11 119	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173.0	no	temsavir 5
FMO3 67	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173.0	no	temsavir 5
BCRP 561	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 35, 179	yes	temsavir 5
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 35, 179	yes	temsavir 5
esterase 72	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 35.0	yes	temsavir 5
CYP3A 191	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 35, 111, 112, 113	yes	temsavir 5	yes (co-administration study) Comment: coadministration of fostemsavir with rifampin significantly decreases temsavir plasma concentrations, reduced temsavir AUC by 80%; coadministration of fostemsavir with drugs that are strong CYP3A inducers result in decreased concentrations of temsavir. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 35, 111, 112, 113

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 69.0		temsavir 5

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY575616	https://www.001chemical.com/chem/864953-29-7
1PlusChem LLC	1P00FCG8	https://www.1pchem.com/search?query=1P00FCG8
AA Blocks	AA00GTZ5	https://www.aablocks.com/goods/Goods/detail?id=AA00GTZ5
AChemBlock	L13964	http://www.achemblock.com/catalogsearch/result/?q=L13964
AK Scientific	3501AH	https://aksci.com/item_detail.php?cat=3501AH
AK Scientific, Inc. (AKSCI)	3502AH	http://www.aksci.com/item_detail.php?cat=3502AH
Acadechem	ACDS-0781672	http://acadechemical.com/product/229218
Achemtek	0102-013953	http://www.achemtek.com/864953-29-7
Adooq BioScience	A15025	https://www.adooq.com/bms-663068.html
Ambinter	Amb22396014	http://www.ambinter.com/reference/22396014
Angene	AGN-PC-0TXRVI	http://www.angenechemical.com/productshow/AGN-PC-0TXRVI.html
Angene	AGN-PC-0WCXR0	http://www.angenechemical.com/productshow/AGN-PC-0WCXR0.html
ApexBio Technology	A3253	https://www.apexbt.com/catalogsearch/result/?q=A3253
AstaTech	43242	http://astatechinc.com/CPSResult.php?CRNO=43242
Aurora Fine Chemicals LLC	A24.141.513	http://online.aurorafinechemicals.com/info?ID=A24.141.513
Aurum Pharmatech LLC	W-5998	http://www.Aurumpharmatech.com/Product/ProductDetails/W_5998
BOC Sciences	864953-29-7	https://www.bocsci.com/bms-663068-cas-864953-29-7-item-84-463659.html
BioChemPartner	BCP13226	http://www.biochempartner.com/864953-29-7-BCP13226
BioCrick	BCC1428	http://www.biocrick.com/BMS-663068-BCC1428.html
Boerchem	BC600763	http://www.boerchem.com/?product_43597.html
Cayman Chemical	18413	http://www.caymanchem.com/app/template/Product.vm/catalog/18413
Chem Scene	CS-1059	http://www.chemscene.com/864953-29-7.html
Chem Scene	CS-0938	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0938
ChemShuttle	155599	https://www.chemshuttle.com/catalogsearch/result/?q=155599
Chemspace	CSSB00137314448	https://chem-space.com/CSSB00137314448
DC Chemicals	DC8163	http://www.dcchemicals.com/product_show-Fostemsavir_BMS_663068_.html
Debye Scientific	DA-35014	https://www.debyesci.com/index.php?id=product&ext[cno]=DA-35014
Excenen	EX-A2034	http://www.excenen.com/searchresultlist.php?id=EX-A2034
Excenen	EX-A1973	https://www.excenen.com/searchresultlist.php?id=864953-29-7
Hairui	FOXF012	http://www.hairuichem.com/en/product/864953-29-7.html
Hairui	FOXF01210	http://www.hairuichem.com/en/product/search.do?q=FOXF01210
KeyOrganics	AS-35292	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-35292
MedChem Express	HY-15440A	https://www.medchemexpress.com/BMS-663068.html
MedChem Express	HY-15440	https://www.medchemexpress.com/search.html?q=HY-15440&ft=&fa=&fp=
MolPort	MolPort-039-137-511	https://www.molport.com/shop/molecule-link/MolPort-039-137-511
MolPort	MolPort-046-703-070	https://www.molport.com/shop/molecule-link/MolPort-046-703-070
Molcore	MC575616	https://www.molcore.com/product/864953-29-7
MuseChem	I005194	https://www.musechem.com/product/I005194.html
Selleck Chemicals	S7220	http://www.selleckchem.com/products/bms-663068.html
ShangHai Biochempartner	BCP09613	http://www.biochempartner.com/search_BCP09613
Smolecule	S528400	http://www.smolecule.com/products/s528400
Synblock Inc	SB11250	http://www.synblock.com/product/864953-29-7.html
THE BioTek	bt-268684	https://www.thebiotek.com/product/inhibitors/bt-268684
THE BioTek	bt-342630	https://www.thebiotek.com/product/others/bt-342630
THE BioTek	bt-464747	https://www.thebiotek.com/product/others/bt-464747
Toronto Research Chemicals	D449298	https://www.trc-canada.com/product-detail/?CatNum=D449298
Toronto Research Chemicals	T017900	https://www.trc-canada.com/product-detail/?CatNum=T017900
eMolecules	44811344	https://orderbb.emolecules.com/search/#?query=44811344
mcule	MCULE-6503554438	https://mcule.com/MCULE-6503554438/

PubMed

Title	Date	PubMed
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.	2016 May	26902761
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.	2017	27922453
[What can new substances offer?].	2017 Jun	28597267
Current Status of the Pharmacokinetics and Pharmacodynamics of HIV-1 Entry Inhibitors and HIV Therapy.	2017 Oct 16	28738768

Patents

Sample Use Guides

In Vivo Use Guide

A phase 2b trial enrolled treatment-experienced adults with HIV infection and randomized study subjects to one of four doses of fostemsavir (400 mg twice daily, 800 mg twice daily, 600 mg once daily, or 1200 mg once daily).

Route of Administration: Oral

In Vitro Use Guide

BMS-626529 (an active moiety of BMS-663068) exhibits an average EC50 against LAI of 0.7 +/-0.4 nM.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 00:30:10 GMT 2023` Edited by `admin` on `Sat Dec 16 00:30:10 GMT 2023`
Record UNII	HJT0M757PN
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FOSTEMSAVIR DISODIUM

Common Name

English

BMS-663068 DISODIUM

Common Name

English

PIPERAZINE, 1-BENZOYL-4-((4-METHOXY-7-(3-METHYL-1H-1,2,4-TRIAZOL-1-YL)-1-((PHOSPHONOOXY)METHYL)-1H-PYRROLO(2,3-C)PYRIDIN-3-YL)OXOACETYL)-, DISODIUM SALT

Systematic Name

English

1,2-ETHANEDIONE, 1-(4-BENZOYL-1-PIPERAZINYL)-2-(4-METHOXY-7-(3-METHYL-1H-1,2,4-TRIAZOL-1-YL)-1-((PHOSPHONOOXY)METHYL)-1H-PYRROLO(2,3-C)PYRIDIN-3-YL)-, SODIUM SALT (1:2)

Systematic Name

English

Code System Code Type Description

CAS

864953-31-1

Created by admin on Sat Dec 16 00:30:10 GMT 2023 , Edited by admin on Sat Dec 16 00:30:10 GMT 2023

PRIMARY

FDA UNII

HJT0M757PN

Created by admin on Sat Dec 16 00:30:10 GMT 2023 , Edited by admin on Sat Dec 16 00:30:10 GMT 2023

PRIMARY

PUBCHEM

46892185

Created by admin on Sat Dec 16 00:30:10 GMT 2023 , Edited by admin on Sat Dec 16 00:30:10 GMT 2023

PRIMARY

Related Record Type Details


					97IQ273H4L

FOSTEMSAVIR

PARENT -> SALT/SOLVATE

Amount:

Related Record Type Details


					97IQ273H4L

FOSTEMSAVIR

ACTIVE MOIETY

AE	Significance	Dose	Population
Nausea	grade 1-4, 10%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Immune reconstitution inflammatory syndrome	grade 1-4, 2%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Somnolence	grade 1-4, 2%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Vomiting	grade 1-4, 2%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Abdominal pain	grade 1-4, 3%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Dyspepsia	grade 1-4, 3%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Fatigue	grade 1-4, 3%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Rash	grade 1-4, 3%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Sleep disturbance	grade 1-4, 3%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Diarrhea	grade 1-4, 4%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Headache	grade 1-4, 4%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Immune reconstitution inflammatory syndrome	grade 3, 3% Disc. AE	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Direct bilirubin increased	grade 3, 7%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Creatinine increased	grade 3-4, 19%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Creatine kinase increased	grade 3-4, 2%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Bilirubin increased	grade 3-4, 3%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
AST increased	grade 3-4, 4%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Hyperglycemia	grade 3-4, 4%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Neutrophils reduced	grade 3-4, 4%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
ALT increased	grade 3-4, 5%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Blood triglycerides increased	grade 3-4, 5%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Lipase increased	grade 3-4, 5%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Hemoglobin decreased	grade 3-4, 6%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: optimized background therapy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years n = 271 Health Status: unhealthy Condition: HIV-1 infection Age Group: 17-43 years Sex: M+F Population Size: 271 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
Abdominal pain	5.6%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: ritonavir(100 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	healthy, 18-49 years n = 18 Health Status: healthy Age Group: 18-49 years Sex: M+F Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/
Nausea	5.6%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: ritonavir(100 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	healthy, 18-49 years n = 18 Health Status: healthy Age Group: 18-49 years Sex: M+F Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/
Scleral icterus	5.6%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: ritonavir(100 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	healthy, 18-49 years n = 18 Health Status: healthy Age Group: 18-49 years Sex: M+F Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/
Abdominal pain	11.1%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: atazanavir(300 mg; oral; 1/day) ritonavir(100 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	healthy, 18-49 years n = 36 Health Status: healthy Age Group: 18-49 years Sex: M+F Population Size: 36 Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/
Headache	13.9%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: atazanavir(300 mg; oral; 1/day) ritonavir(100 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	healthy, 18-49 years n = 36 Health Status: healthy Age Group: 18-49 years Sex: M+F Population Size: 36 Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/
Musculoskeletal chest pain	2.8%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: atazanavir(300 mg; oral; 1/day) ritonavir(100 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	healthy, 18-49 years n = 36 Health Status: healthy Age Group: 18-49 years Sex: M+F Population Size: 36 Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/
Scleral icterus	27.8%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: atazanavir(300 mg; oral; 1/day) ritonavir(100 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	healthy, 18-49 years n = 36 Health Status: healthy Age Group: 18-49 years Sex: M+F Population Size: 36 Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/
Dizziness	5.6%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: atazanavir(300 mg; oral; 1/day) ritonavir(100 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	healthy, 18-49 years n = 36 Health Status: healthy Age Group: 18-49 years Sex: M+F Population Size: 36 Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/
Nausea	8.3%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Co-administed with:: atazanavir(300 mg; oral; 1/day) ritonavir(100 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	healthy, 18-49 years n = 36 Health Status: healthy Age Group: 18-49 years Sex: M+F Population Size: 36 Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/
Headache	5.6%	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	healthy, 18-49 years n = 36 Health Status: healthy Age Group: 18-49 years Sex: M+F Population Size: 36 Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/
Headache	grade 1, 14%	1050 mg 2 times / day steady, oral (mean) Studied dose Dose: 1050 mg, 2 times / day Route: oral Route: steady Dose: 1050 mg, 2 times / day Co-administed with:: raltegravir and tenofovir disoproxil fumarate Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	unhealthy, adults n = 200 Health Status: unhealthy Condition: HIV-1 infection Age Group: adults Sex: M+F Population Size: 200 Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/
Back pain	2% Disc. AE	1200 mg 1 times / day steady, oral Studied dose Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Co-administed with:: raltegravir and tenofovir disoproxil fumarate Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	unhealthy, adults n = 50 Health Status: unhealthy Condition: HIV-1 infection Age Group: adults Sex: M+F Population Size: 50 Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/
Disseminated tuberculosis	2% Disc. AE	1200 mg 1 times / day steady, oral Studied dose Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Co-administed with:: raltegravir and tenofovir disoproxil fumarate Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	unhealthy, adults n = 50 Health Status: unhealthy Condition: HIV-1 infection Age Group: adults Sex: M+F Population Size: 50 Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/
Ischaemia	2% Disc. AE	400 mg 2 times / day steady, oral Studied dose Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Co-administed with:: raltegravir and tenofovir disoproxil fumarate Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	unhealthy, adults n = 50 Health Status: unhealthy Condition: HIV-1 infection Age Group: adults Sex: M+F Population Size: 50 Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/
Acute renal failure	2% Disc. AE	800 mg 2 times / day steady, oral Studied dose Dose: 800 mg, 2 times / day Route: oral Route: steady Dose: 800 mg, 2 times / day Co-administed with:: raltegravir and tenofovir disoproxil fumarate Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	unhealthy, adults n = 49 Health Status: unhealthy Condition: HIV-1 infection Age Group: adults Sex: M+F Population Size: 49 Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/
Bone tuberculosis	2% Disc. AE	800 mg 2 times / day steady, oral Studied dose Dose: 800 mg, 2 times / day Route: oral Route: steady Dose: 800 mg, 2 times / day Co-administed with:: raltegravir and tenofovir disoproxil fumarate Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	unhealthy, adults n = 49 Health Status: unhealthy Condition: HIV-1 infection Age Group: adults Sex: M+F Population Size: 49 Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/
QT interval prolonged		2400 mg 2 times / day steady, oral Highest studied dose Dose: 2400 mg, 2 times / day Route: oral Route: steady Dose: 2400 mg, 2 times / day Sources: https://www.fda.gov/media/140641/download	healthy n = 15 Health Status: healthy Population Size: 15 Sources: https://www.fda.gov/media/140641/download

Details

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound

Drug as perpetrator